Addictions
Alberta’s recovery-focused addiction agency to address data gap
By Alexandra Keeler
The launch of Alberta’s Centre of Recovery Excellence comes as Ontario and Saskatchewan also shift to recovery-oriented models
This fall, Alberta will be launching a new agency to lead recovery-focused addiction research and treatment in the province.
The Canadian Centre of Recovery Excellence (CoRE) aims to address a major challenge in Canada’s toxic drug crisis: a shortage of evidence-based, recovery-oriented research.
“[W]e hope to … support individuals on their recovery journey using the best available evidence on what works and what does not work,” the centre’s communications lead Katy Merrifield told Canadian Affairs in a written statement.
“There is also a lack of tangible research centred on the outcomes of recovery-focused policy, which is what CoRE aims to address,” she said.
The move comes at a time when Ontario and Saskatchewan are also shifting their policy responses away from harm-reduction strategies — such as safe consumption sites and needle exchange programs — toward more recovery-oriented models.
Last week, Ontario announced it would be closing 10 safe consumption sites located near daycares and schools and opening 19 recovery hubs. It also plans to prevent municipalities from establishing new consumption sites, requesting the decriminalization of illegal drugs or participating in federal safe supply initiatives, Canadian Affairs reported last week.
Early signs of success
CoRE’s launch is part of Alberta’s broader approach to addiction under the United Conservative Party government. The party, which has been in power since 2019, favours a recovery-oriented approach over a harm-reduction model.
In 2019, Alberta committed $140 million over four years to enhance addiction services, which has increased the number of available treatment spaces from 19,000 to 29,400. The province has eliminated a $40-a-day user fee at publicly funded addiction treatment facilities. And it has authorized police officers to assist detainees in seeking treatment.
The number of opioid-related deaths in the first three months of 2024 was 452, down from a high of 627 deaths in Q1 2023. However, it is still above the 241 deaths registered in the first quarter of 2020, according to the Alberta Substance Use Surveillance System.
Despite these early signs of success, the province would like to see further data to support its recovery-focused policy decisions.
“There is no clear centre of recovery excellence that can advise on what works and does not work when it comes to mental health and addictions,” Alberta’s Minister of Mental Health and Addiction Dan Williams said April 2 when announcing the creation of CoRE.
“One challenge with addiction research, and research in general, is there is often an attempt to look at a very specific intervention over a short period of time,” said Merrified. “[B]roader, long-term research is time consuming and expensive.”
CoRE will investigate the number of Albertans affected by addiction, their recovery journeys and outcomes, such as return to work, access to housing and family reunification.
The agency also plans to integrate global best practices into Alberta’s programs.
“From Portugal’s commission for drug dissuasion combined with their massive scale of recovery spaces to Italy’s use of recovery communities, we look forward to incorporating global lessons where applicable,” said Merrifield.
Subscribe for free to get BTN’s latest news and analysis – or donate to our investigative journalism fund.
Industry funding
Alberta’s 2024 budget committed $5 million in funding to launch CoRE.
Merrifield says CoRE’s funding structure will be a key point of distinction between it and the British Columbia Centre on Substance Use, which is another key player in addiction research and education.
In contrast to CoRE, the B.C. centre prioritizes addiction medicine and harm reduction.
“Our vision is to enable the well-being of people who use substances through evidence-informed, stigma-free policies,” the centre’s website says.
“CoRE has safeguards enshrined in legislation to protect against receiving external funding that could be seen as attempting to bias research results,” said Merrifield, noting the centre will not accept industry funding from pharmaceutical or cannabis companies.
By contrast, the British Columbia Centre on Substance Use does receive funding from the pharmaceutical company Indivior, the pharmacy chain Shoppers Drug Mart and the cannabis companies Tilray and Canopy Growth.
Indivior is the maker of Suboxone, a medication prescribed for opioid dependence. Indivior is currently the subject of at least two class-action lawsuits alleging Indivior failed to disclose Suboxone’s adverse side effects, Canadian Affairs reported in August.
In 2021, Shoppers Drug Mart offered a $2-million gift to the University of British Columbia to establish a pharmacy fellowship and support the education of pharmacist-focused addiction treatment at the British Columbia Centre on Substance Use.
Asked about the risk that drug industry funding could compromise the objectivity of their research, the B.C. centre referred Canadian Affairs to their website’s funding page. The website states their research is supported by peer-reviewed grants and independent ethical reviews to ensure objectivity.
Similar programs
Kevin Hollett, communications lead for the British Columbia Centre on Substance Use, said the centre is willing to collaborate with CoRE.
“We would welcome opportunities to collaborate and share knowledge with the CoRE team following their operational launch and as they define their research scope,” he said in a written statement.
CoRE was initially slated to be operational this summer, but launch details have not yet been announced.
At a conference on April 4, Minister Williams announced plans for CoRE to collaborate with Ontario and Saskatchewan on recovery-focused treatment systems. Currently, both provinces lack a direct equivalent to CoRE or B.C.’s centre.
“Many jurisdictions are interested in learning from the Alberta Recovery Model and implementing similar programs,” said Merrifield.
This article was produced through the Breaking Needles Fellowship Program, which provided a grant to Canadian Affairs, a digital media outlet, to fund journalism on addiction and crime in Canada. Articles produced through the Fellowship are co-published by Break The Needle and Canadian Affairs.
Break The Needle. Our content is always free – but if you want to help us commission more high-quality journalism, consider getting a voluntary paid subscription.
Addictions
The War on Commonsense Nicotine Regulation
From the Brownstone Institute
Cigarettes kill nearly half a million Americans each year. Everyone knows it, including the Food and Drug Administration. Yet while the most lethal nicotine product remains on sale in every gas station, the FDA continues to block or delay far safer alternatives.
Nicotine pouches—small, smokeless packets tucked under the lip—deliver nicotine without burning tobacco. They eliminate the tar, carbon monoxide, and carcinogens that make cigarettes so deadly. The logic of harm reduction couldn’t be clearer: if smokers can get nicotine without smoke, millions of lives could be saved.
Sweden has already proven the point. Through widespread use of snus and nicotine pouches, the country has cut daily smoking to about 5 percent, the lowest rate in Europe. Lung-cancer deaths are less than half the continental average. This “Swedish Experience” shows that when adults are given safer options, they switch voluntarily—no prohibition required.
In the United States, however, the FDA’s tobacco division has turned this logic on its head. Since Congress gave it sweeping authority in 2009, the agency has demanded that every new product undergo a Premarket Tobacco Product Application, or PMTA, proving it is “appropriate for the protection of public health.” That sounds reasonable until you see how the process works.
Manufacturers must spend millions on speculative modeling about how their products might affect every segment of society—smokers, nonsmokers, youth, and future generations—before they can even reach the market. Unsurprisingly, almost all PMTAs have been denied or shelved. Reduced-risk products sit in limbo while Marlboros and Newports remain untouched.
Only this January did the agency relent slightly, authorizing 20 ZYN nicotine-pouch products made by Swedish Match, now owned by Philip Morris. The FDA admitted the obvious: “The data show that these specific products are appropriate for the protection of public health.” The toxic-chemical levels were far lower than in cigarettes, and adult smokers were more likely to switch than teens were to start.
The decision should have been a turning point. Instead, it exposed the double standard. Other pouch makers—especially smaller firms from Sweden and the US, such as NOAT—remain locked out of the legal market even when their products meet the same technical standards.
The FDA’s inaction has created a black market dominated by unregulated imports, many from China. According to my own research, roughly 85 percent of pouches now sold in convenience stores are technically illegal.
The agency claims that this heavy-handed approach protects kids. But youth pouch use in the US remains very low—about 1.5 percent of high-school students according to the latest National Youth Tobacco Survey—while nearly 30 million American adults still smoke. Denying safer products to millions of addicted adults because a tiny fraction of teens might experiment is the opposite of public-health logic.
There’s a better path. The FDA should base its decisions on science, not fear. If a product dramatically reduces exposure to harmful chemicals, meets strict packaging and marketing standards, and enforces Tobacco 21 age verification, it should be allowed on the market. Population-level effects can be monitored afterward through real-world data on switching and youth use. That’s how drug and vaccine regulation already works.
Sweden’s evidence shows the results of a pragmatic approach: a near-smoke-free society achieved through consumer choice, not coercion. The FDA’s own approval of ZYN proves that such products can meet its legal standard for protecting public health. The next step is consistency—apply the same rules to everyone.
Combustion, not nicotine, is the killer. Until the FDA acts on that simple truth, it will keep protecting the cigarette industry it was supposed to regulate.
Addictions
The Shaky Science Behind Harm Reduction and Pediatric Gender Medicine

By Adam Zivo
Both are shaped by radical LGBTQ activism and questionable evidence.
Over the past decade, North America embraced two disastrous public health movements: pediatric gender medicine and “harm reduction” for drug use. Though seemingly unrelated, these movements are actually ideological siblings. Both were profoundly shaped by extremist LGBTQ activism, and both have produced grievous harms by prioritizing ideology over high-quality scientific evidence.
While harm reductionists are known today for championing interventions that supposedly minimize the negative effects of drug consumption, their movement has always been connected to radical “queer” activism. This alliance began during the 1980s AIDS crisis, when some LGBTQ activists, hoping to reduce HIV infections, partnered with addicts and drug-reform advocates to run underground needle exchanges.
The Bureau is a reader-supported publication.
To receive new posts and support my work, consider becoming a free or paid subscriber.
In the early 2000s, after the North American AIDS epidemic was brought under control, many HIV organizations maintained their relevance (and funding) by pivoting to addiction issues. Despite having no background in addiction medicine, their experience with drug users in the context of infectious diseases helped them position themselves as domain experts.
These organizations tended to conceptualize addiction as an incurable infection—akin to AIDS or Hepatitis C—and as a permanent disability. They were heavily staffed by progressives who, influenced by radical theory, saw addicts as a persecuted minority group. According to them, drug use itself was not the real problem—only society’s “moralizing” norms.
These factors drove many HIV organizations to lobby aggressively for harm reduction at the expense of recovery-oriented care. Their efforts proved highly successful in Canada, where I am based, as HIV researchers were a driving force behind the implementation of supervised consumption sites and “safer supply” (free, government-supplied recreational drugs for addicts).
From the 2010s onward, the association between harm reductionism and queer radicalism only strengthened, thanks to the popularization of “intersectional” social justice activism that emphasized overlapping forms of societal oppression. Progressive advocates demanded that “marginalized” groups, including drug addicts and the LGBTQ community, show enthusiastic solidarity with one another.
These two activist camps sometimes worked on the same issues. For example, the gay community is struggling with a silent epidemic of “chemsex” (a dangerous combination of drugs and anonymous sex), which harm reductionists and queer theorists collaboratively whitewash as a “life-affirming cultural practice” that fosters “belonging.”
For the most part, though, the alliance has been characterized by shared tones and tactics—and bad epistemology. Both groups deploy politicized, low-quality research produced by ideologically driven activist-researchers. The “evidence-base” for pediatric gender medicine, for example, consists of a large number of methodologically weak studies. These often use small, non-representative samples to justify specious claims about positive outcomes. Similarly, harm reduction researchers regularly conduct semi-structured interviews with small groups of drug users. Ignoring obvious limitations, they treat this testimony as objective evidence that pro-drug policies work or are desirable.
Gender clinicians and harm reductionists are also averse to politically inconvenient data. Gender clinicians have failed to track long-term patient outcomes for medically transitioned children. In some cases, they have shunned detransitioners and excluded them from their research. Harm reductionists have conspicuously ignored the input of former addicts, who generally oppose laissez-faire drug policies, and of non-addict community members who live near harm-reduction sites.
Both fields have inflated the benefits of their interventions while concealing grievous harms. Many vulnerable children, whose gender dysphoria otherwise might have resolved naturally, were chemically castrated and given unnecessary surgeries. In parallel, supervised consumption sites and “safer supply” entrenched addiction, normalized public drug use, flooded communities with opioids, and worsened public disorder—all without saving lives.
In both domains, some experts warned about poor research practices and unmeasured harms but were silenced by activists and ideologically captured institutions. In 2015, one of Canada’s leading sexologists, Kenneth Zucker, was fired from the gender clinic he had led for decades because he opposed automatically affirming young trans-identifying patients. Analogously, dozens of Canadian health-care professionals have told me that they feared publicly criticizing aspects of the harm-reduction movement. They thought doing so could invite activist harassment while jeopardizing their jobs and grants.
By bullying critics into silence, radical activists manufactured false consensus around their projects. The harm reductionists insist, against the evidence, that safer supply saves lives. Their idea of “evidence-based policymaking” amounts to giving addicts whatever they ask for. “The science is settled!” shout the supporters of pediatric gender medicine, though several systematic reviews proved it was not.
Both movements have faced a backlash in recent years. Jurisdictions throughout the world are, thankfully, curtailing irreversible medical procedures for gender-confused youth and shifting toward a psychotherapy-based “wait and see” approach. Drug decriminalization and safer supply are mostly dead in North America and have been increasingly disavowed by once-supportive political leaders.
Harm reductionists and queer activists are trying to salvage their broken experiments, occasionally by drawing explicit parallels between their twin movements. A 2025 paper published in the International Journal of Drug Policy, for example, asserts that “efforts to control, repress, and punish drug use and queer and trans existence are rising as right-wing extremism becomes increasingly mainstream.” As such, there is an urgent need to “cultivate shared solidarity and action . . . whether by attending protests, contacting elected officials, or vocally defending these groups in hostile spaces.”
How should critics respond? They should agree with their opponents that these two radical movements are linked—and emphasize that this is, in fact, a bad thing. Large swathes of the public understand that chemically and surgically altering vulnerable children is harmful, and that addicts shouldn’t be allowed to commandeer public spaces. Helping more people grasp why these phenomena arose concurrently could help consolidate public support for reform and facilitate a return to more restrained policies.
Adam Zivo is director of the Canadian Centre for Responsible Drug Policy.
For the full experience, please upgrade your subscription and support a public interest startup.
We break international stories and this requires elite expertise, time and legal costs.
-
Business1 day agoCarney budget doubles down on Trudeau-era policies
-
espionage2 days agoU.S. Charges Three More Chinese Scholars in Wuhan Bio-Smuggling Case, Citing Pattern of Foreign Exploitation in American Research Labs
-
COVID-191 day agoCrown still working to put Lich and Barber in jail
-
Business1 day agoCarney’s Deficit Numbers Deserve Scrutiny After Trudeau’s Forecasting Failures
-
Business1 day agoCarney budget continues misguided ‘Build Canada Homes’ approach
-
International1 day agoKazakhstan joins Abraham Accords, Trump says more nations lining up for peace
-
armed forces15 hours agoIt’s time for Canada to remember, the heroes of Kapyong
-
Business1 day agoHere’s what pundits and analysts get wrong about the Carney government’s first budget






